Comparing a biosimilar follitropin alfa (Cinnal-f®) with Gonal-f® in women undergoing ovarian stimulation: An RCT

  • سال انتشار: 1400
  • محل انتشار: مجله طب تولید مثل ایران، دوره: 19، شماره: 11
  • کد COI اختصاصی: JR_IJRM-19-11_008
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 341
دانلود فایل این مقاله

نویسندگان

Batool Hossein Rashidi

Vali-e-Asr Reproductive Health Research Centre, Tehran University of Medical Sciences, Tehran, Iran.

Khashayar Sayyari

Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Ramin Heshmat

Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Saeid Amanpour

Vali-e-Asr Reproductive Health Research Centre, Tehran University of Medical Sciences, Tehran, Iran.

Ensieh Shahrokh Tehraninejad

Vali-e-Asr Reproductive Health Research Centre, Tehran University of Medical Sciences, Tehran, Iran.

Masoumeh Masoumi

Vali-e-Asr Reproductive Health Research Centre, Tehran University of Medical Sciences, Tehran, Iran.

Farhang Rezaei

Medical Department, Orchid Pharmed Company, Tehran, Iran.

چکیده

Background: Advances in recombinant DNA technology led to the development of recombinant follitropin alfa. Recombinant human follicle-stimulating hormone products are used to stimulate follicular maturation. Objective: To compare the efficacy and safety of a biosimilar-candidate recombinant human follicle-stimulating hormone (Cinnal-f®; CinnaGen, Iran) with the reference product (Gonal-f®; Merck Serono, Germany) in women undergoing ovarian stimulation for intracytoplasmic sperm injection (ICSI). Materials and Methods: In this randomized controlled trial, a total sample size of ۲۰۰ women (age < ۳۵ yr, candidate for ICSI) was calculated. Participants began a pituitary downregulation protocol with buserelin. They received ۱۵۰ IU daily of either Cinnal-f® or Gonal-f® from the second day of their cycle. The primary outcome of the study was the percentage of metaphase II (MII) oocytes. The secondary outcomes included the number and quality of oocytes retrieved, duration of stimulation, fertilization rate, embryo quality, the number of clinical and ongoing pregnancies, and the incidence of ovarian hyperstimulation syndrome (as an important safety marker). Results: A total of ۲۰۸ women were enrolled, of whom, ۲۰۰ completed the study period. Ovarian stimulation with Cinnal-f® resulted in a comparable percentage of MII oocytes as with Gonal-f® (۷۸.۶۴% vs ۸۰.۰۲%, respectively; p = ۰.۸۱). No statistically significant difference was seen in the secondary outcomes between the groups. Conclusion: Cinnal-f® proved non-inferior to Gonal-f®, based on the percentage of MII oocytes in women aged < ۳۵ yr undergoing ICSI. Our findings confirm that the efficacy and safety profiles of Cinnal-f® and Gonal-f® are similar.

کلیدواژه ها

Follitropin alfa, Biosimilar, Efficacy, Safety, Intracytoplasmic sperm injection., فولیتروپین آلفا, بیوسیمیلار, اثربخشی, ایمنی, تزریق اسپرم داخل سیتوپلاسمی.

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.